Program
elebsiran
Also written as “VIR-2218”, “Elebsiran” and “BRII-835 (VIR-2218)”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis · Renal Insufficiency · Fibrosis · Hepatitis D, Chronic, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vir Biotechnology | 84 open or running | phase 3since Mar 24, 2025 | Sep 11, 2018 | Nov 2026phase 2 · NCT07142811 |
| Brii Biosciences | 20 open or running | phase 2since Aug 7, 2020 | Aug 7, 2020 | none ahead |
| Virion Therapeutics | 10 open or running | phase 1since Sep 20, 2023 | Sep 20, 2023 | none ahead |
Also a collaborator on its studies: vbi-vaccines-inc and Alnylam Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2018First study: phase 2 study in Hepatitis B, ChronicNew to Vir BiotechnologyVir Biotechnology · NCT03672188 · 82 enrolled · Australia, Hong Kong, Korea, Republic of and more
- May 29, 2020Phase 2 study in Hepatitis B, ChronicVir Biotechnology · NCT04412863 · 84 enrolled · Australia, Hong Kong, Malaysia and more
- Aug 7, 2020Brii Biosciences's first study: phase 2 study in Hepatitis B, ChronicNew to Brii BiosciencesBrii Biosciences · NCT04507269 · 21 enrolled · China
- Feb 7, 2021Phase 2 study in Hepatitis B, ChronicBrii Biosciences · NCT04749368 · 91 enrolled · Australia, China, New Zealand and more
- Jul 1, 2022Phase 2 study in Hepatitis D, ChronicVir Biotechnology · NCT05461170 · 95 enrolled · Bulgaria, France, Germany and more
- Jul 15, 2022Phase 1 study in FibrosisVir Biotechnology · NCT05484206 · 88 enrolled · United States
- Apr 24, 2023Phase 1 study in Renal InsufficiencyVir Biotechnology · NCT05844228 · 28 enrolled · United States
- Sep 20, 2023Virion Therapeutics's first study: phase 1 study in Hepatitis B, ChronicNew to Virion TherapeuticsVirion Therapeutics · NCT06070051 · 35 enrolled · Hong Kong, New Zealand
- Mar 24, 2025Phase 3 study in HepatitisVir Biotechnology · NCT06903338 · 124 enrolled · United States, Canada, Georgia and more
- Aug 13, 2025Phase 3 study in HepatitisVir Biotechnology · NCT07128550 · 150 enrolled · Austria, France, Germany and more
- Aug 19, 2025Phase 2 study in HepatitisVir Biotechnology · NCT07142811 · 100 enrolled · Belgium, Bulgaria, France and more
Ahead
- Nov 2026Primary completion: phase 2 study in HepatitisVir Biotechnology · NCT07142811
- Dec 2026Primary completion: phase 3 study in HepatitisVir Biotechnology · NCT07128550
- Nov 2031Primary completion: phase 2 study in Hepatitis D, ChronicVir Biotechnology · NCT05461170
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07142811Hepatitis · Belgium, Bulgaria, France and more | 2 | Active, not recruiting | Vir Biotechnology | Nov 2026 | 100 |
| NCT07128550Hepatitis · Austria, France, Germany and more | 3 | Active, not recruiting | Vir Biotechnology | Dec 2026 | 150 |
| NCT06903338Hepatitis · United States, Canada, Georgia and more | 3 | Active, not recruiting | Vir Biotechnology | Sep 30, 2026 | 124 |
| NCT06070051Hepatitis B, Chronic · Hong Kong, New Zealand | 1 | Completed | Virion Therapeutics | Mar 31, 2026 | 35 |
| NCT05844228Renal Insufficiency · United States | 1 | Completed | Vir Biotechnology | Mar 1, 2025 | 28 |
| NCT05484206Fibrosis · United States | 1 | Completed | Vir Biotechnology | Dec 9, 2025 | 88 |
| NCT05461170Hepatitis D, Chronic · Bulgaria, France, Germany and more | 2 | Active, not recruiting | Vir Biotechnology | Nov 2031 | 95 |
| NCT04749368Hepatitis B, Chronic · Australia, China, New Zealand and more | 2 | Completed | Brii Biosciences | Jul 4, 2023 | 91 |
| NCT04507269Hepatitis B, Chronic · China | 2 | Completed | Brii Biosciences | Sep 30, 2021 | 21 |
| NCT04412863Hepatitis B, Chronic · Australia, Hong Kong, Malaysia and more | 2 | Completed | Vir Biotechnology | Mar 25, 2024 | 84 |
| NCT03672188Hepatitis B, Chronic · Australia, Hong Kong, Korea, Republic of and more | 2 | Completed | Vir Biotechnology | Sep 3, 2020 | 82 |
How it is read
Names in the registry
- “VIR-2218”, 7 entries
- “Elebsiran”, 3 entries
- “BRII-835 (VIR-2218)”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 5 studies
- Hepatitis, 3 studies
- Renal Insufficiency, 1 study
- Fibrosis, 1 study
- Hepatitis D, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.